Additionally, treatment with brusatol is a pharmacological inhibitor of NFE2L2 and improved the sensitivity of AML cell lines to daunorubicin, arsenic trioxide, and cytarabine [38]. The gene discussed is NFE2L2; the disease is acute myeloid leukemia.